Arvinas
Pfizer and Arvinas Abandon Commercialization of PROTAC Inhibitor, Triggering Layoffs and Pipeline Refocus
Pfizer; Arvinas; PROTAC; vepdegestrant; layoffs; out-licensing; FDA; breast cancer; oncology; CDK inhibitors
Kathy High Takes Helm at GV, ARCH-Backed Eye Disease Biotech RhyGaze; Arvinas Sees Leadership Shift
Kathy High, RhyGaze, GV, ARCH, eye disease biotech, Arvinas, leadership changes
Novartis Secures $1B Protein Degrader Deal with Arvinas and Initiates MorphoSys Tender Offer
Novartis, Arvinas, Protein Degrader Deal, PROTAC® Androgen Receptor Degrader, MorphoSys Tender Offer